Vascular Disrupting Agents : market Growth, Share, Size , Segmentations , Major players, Collaborations & Agreements , Regional Study and Forecast by 2031

According to the latest research by Insight Analytics, The Vascular Disrupting Agents Market Size is estimated to be worth 105.42 Million in 2022 and is expected to grow to 2298.64 Million by 2031, with a compound annual growth rate (CAGR) of 41.4% during the forecast period of 2023-2031.

Download Free Sample Pages @ https://www.insightaceanalytic.com/request-sample/1299

The extant tumour neovasculature is the primary target of a novel family of cancer medications known as vascular-disrupting agents (VDAs), which have a low toxicity profile. VDAs generally do not exhibit overlapping adverse effects when administered with conventional cytotoxics. Combined with a variety of common cytotoxics, a novel family of effective anticancer drugs known as vascular-disrupting agents demonstrates synergistic and additive effects. It is imperative to continue assessing the most effective drug interactions and combinations of VDAs with other drug classes from a pharmacological perspective.

The market for vascular disrupting agents is influenced by a variety of factors, including the high prevalence of cancer, the rapidly expanding geriatric population, the increasing demand for advanced cancer therapy options, the growing public awareness of novel therapy treatments, the rising government expenditure for cancer therapy research and development, the expiration of patents for various drugs, and changing lifestyle standards. Pharmaceutical companies have also increased their investments in cancer research as a result of the increasing number of risk factors and cancer-causing substances in anticancer therapy. This has created new growth prospects for the market for vascular-disrupting agents. Nevertheless, the future expansion of the market may be constrained by the high prices of target treatments and the need for more safety evidence.

It is anticipated that North America will make a significant contribution to the Vascular Disrupting Agents market in the future. This increase is attributed to the region's increasing emphasis on drug development and biologics, as well as the presence of well-established pharmaceutical and biotechnology firms. The necessity for personalized remedies has also been exacerbated by the region's increasing cancer incidence. Furthermore, it is anticipated that the Asia Pacific Vascular Disrupting Agents market will experience substantial growth during the forecast period. It is expected that the region's prosperity will be supported by a rising investment in research and development and a robust healthcare infrastructure during the projected period.

Enquiry For Before Buying this Report @ https://www.insightaceanalytic.com/enquiry-before-buying/1299

Major market players operating in the Vascular Disrupting Agents market include

• Madrigal Pharmaceuticals, Inc.
• Celgene Corporation
• Bionomics Ltd.
• Mateon Therapeutics
• Myrexis
• VBL Therapeutics
• Nereus Pharmaceuticals
• Lees Pharmaceutical Holdings.
• Steba biotech
• BeyondSpring Pharmaceuticals
• AGC Biologics
• Avid Bioservices
• Bionomics
• Beijing Shenogen Biomedical
• Immune Pharmaceuticals

Recent collaborations and agreements in the market:

• In December 2021, the US Food and Drug Administration (FDA) issued a complete response letter (CRL) (CIN) in response to BeyondSpring Pharmaceuticals' new drug application (NDA) that sought approval for plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) to prevent chemotherapy-induced neutropenia.

• In June 2021, VBL Therapeutics (Israel) provided updates on the ongoing OVAL Phase 3 study, which is examining ofranergene obadenovec (VB-111) for the treatment of platinum-resistant ovarian cancer.

Purchase this Report Directly Here https://www.insightaceanalytic.com/buy-report/1299

Market Segments

Global Vascular Disrupting Agents Market, by Indications

• Non-Small Cell Lung Cancer
• Prostate Cancer
• Glioblastoma
• Renal Pelvis
• Ureter Cancer
• Liver Cancer
• Chemotherapy-Induced Neutropenia
• Mesothelioma
• Ovarian Cancer

Global Vascular Disrupting Agents Market, by Therapeutic Area
• Solid Tumors
• Hematological Malignancies

Global Vascular Disrupting Agents Market, by Molecules
• Flavonoids
• Tubulin Binding Agents
• Ligand-Directed Agents

Global Vascular Disrupting Agents Market, by Therapy
• Combination
• Mono

Global Vascular Disrupting Agents Market, by Route of Administration
• Intravenous
• Oral

Global Vascular Disrupting Agents Market, by Product
• Plinabulin
• VB-111
• Icaritin
• NGR-TNF
• Bavituximab
• Padeliporfin
• Others

For More Information @ https://www.insightaceanalytic.com/customisation/1299

Global Vascular Disrupting Agents Market, by Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Vascular Disrupting Agents Market
• U.S.
• Canada

Europe Vascular Disrupting Agents Market
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Vascular Disrupting Agents Market
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Vascular Disrupting Agents Market
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Vascular Disrupting Agents Market
• GCC Countries
• South Africa
o Rest of Middle East & Africa

Get Full Information On this Market Insight @ https://www.insightaceanalytic.com/report/global-vascular-disrupting-agents-market/1299

Contact Us:

InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis of key market insights in a timely and cost-effective manner.

This release was published on openPR.